Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London.
Stocks · News reference
Lexicon Pharmaceuticals released baseline patient demographic data for its ongoing Phase 3 SONATA-HCM clinical trial evaluating sotagliflozin in patients with symptomatic hypertrophic cardiomyopathy.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London.
Citigroup maintained a Buy rating on Lexicon Pharmaceuticals and increased its price target from $3.10 to $3.40.
Lexicon Pharmaceuticals announced new data from two investigator-initiated studies highlighting the cardiovascular effects of its dual SGLT1/2 inhibitor, sotagliflozin.
Lexicon Pharmaceuticals reported a net loss of $14.0 million for the third quarter of 2026 and provided updates on its clinical milestones, including progress in its collaboration with Novo Nordisk.